PHASE II ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS WITH DECREASED BONE D

II 期每周一次阿仑膦酸钠用于骨 D 减少的 HIV 感染者

• 批准号: 7377472
• 负责人: DAVID A WOHL
• 金额: $ 2.21万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377472
• 关键词: PHASE; II; ONCE; WEEKLY; ALENDRONATE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The main purpose of this study is to find out if alendronate plus calcium and vitamin D is well tolerated, effective and safe to treat bone loss in persons with HIV infection compared to calcium and vitamin D alone.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究的主要目的是找出与单独使用钙和维生素D相比，阿伦磷酸钠加钙和维生素D治疗HIV感染者的骨丢失是否具有良好的耐受性、有效性和安全性。